article · European Heart Journal
This international INTERASPIRE study investigated whether guideline standards for secondary prevention and cardiac rehabilitation are being met in coronary heart disease (CHD) patients. Researchers interviewed and examined 4548 adults across 14 countries, approximately one year after their hospitalisation for CHD. The findings revealed that only 38.6% achieved target blood pressure and 16.6% reached target LDL cholesterol levels. Nearly half of patients who smoked at hospitalisation continued to do so. Females were less likely to meet these targets than males. Overall, only 9.0% reported attending cardiac rehabilitation, and a mere 1.0% achieved optimal guideline adherence. The study concludes that there is inadequate and varied implementation of secondary prevention guidelines globally, with significant geographic and sex disparities.
This research highlights critical gaps in the care of coronary heart disease patients after hospitalisation, showing that many do not receive or adhere to recommended secondary prevention. Addressing these disparities and improving guideline implementation could significantly reduce the burden of heart disease and improve patient outcomes globally.
The abstract does not indicate a direct application pathway, specific user, or readiness level for commercialisation. It identifies a widespread problem in healthcare delivery and adherence to guidelines for secondary prevention of coronary heart disease. The findings could inform policy changes, public health campaigns, and the development of new healthcare programmes or interventions aimed at improving patient adherence and guideline implementation.
AI-generated from the published abstract. Always read the original work before citing.
BACKGROUND AND AIMS: INTERASPIRE is an international study of coronary heart disease (CHD) patients, designed to measure if guideline standards for secondary prevention and cardiac rehabilitation are being achieved in a timely manner. METHODS: Between 2020 and 2023, adults hospitalized in the preceding 6-24 months with incident or recurrent CHD were sampled in 14 countries from all 6 World Health Organization regions and invited for a standardized interview and examination. Direct age and sex standardization was used for country-level prevalence estimation. RESULTS: Overall, 4548 (21.1% female) CHD patients were interviewed a median of 1.05 (interquartile range .76-1.45) years after index hospitalization. Among all participants, 24.6% were obese (40.7% centrally). Only 38.6% achieved a blood pressure (BP) < 130/80 mmHg and 16.6% a LDL cholesterol (LDL-C) of <1.4 mmol/L. Of those smoking at hospitalization, 48% persisted at interview. Of those with known diabetes, 55.2% achieved glycated haemoglobin (HbA1c) of <7.0%. A further 9.8% had undetected diabetes and 26.9% impaired glucose tolerance. Females were less likely to achieve the targets: BP (females 36.8%, males 38.9%), LDL-C (females 12.0%, males 17.9%), and HbA1c in diabetes (females 47.7%, males 57.5%). Overall, just 9.0% (inter-country range 3.8%-20.0%) reported attending cardiac rehabilitation and 1.0% (inter-country range .0%-2.4%) achieved the study definition of optimal guideline adherence. CONCLUSIONS: INTERASPIRE demonstrates inadequate and heterogeneous international implementation of guideline standards for secondary prevention in the first year after CHD hospitalization, with geographic and sex disparity. Investment aimed at reducing between-country and between-individual variability in secondary prevention will promote equity in global efforts to reduce the burden of CHD.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1093/eurheartj/ehae558
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
